Can ancient herbs and modern therapy help ovarian cancer patients sleep better and live longer?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 18 to 80 years (inclusive). 2. Performance status (PS) score of 0-2. 3. Histologically or cytologically confirmed primary epithelial ovarian carcinoma, with postoperative FIGO stage III-IV, and scheduled to receive postoperative standard first-line platinum-based chemotherapy. 4. Having undergone ovarian cancer debulking surgery, in a stable condition at enrollment (no active infection, no severe hepatic or renal impairment, etc.), and planned for postoperative first-line platinum-based chemotherapy. 5. Meeting the diagnostic criteria for ovarian cancer-related insomnia (difficulty initiating sleep, sleep maintenance disturbance \[nocturnal awakening ≥2 times\], early morning awakening with inability to return to sleep, occurring ≥3 times per week and lasting ≥1 month). 6. Possess the ability to comprehend assessment scales and undergo Cognitive Behavioral Therapy for Insomnia (e.g., Mini-Mental State Examination score ≥24, or education level above primary school). 7. Voluntarily sign the informed consent form, agree to receive the study treatment, and able to independently complete a sleep diary. Exclusion Criteria: 1. Previous systematic treatment with Cognitive Behavioral Therapy for Insomnia. 2. History of chronic insomnia, depression, or other psychiatric disorders prior to ovarian cancer diagnosis, AND with a Patient Health Questionnaire-9 score ≥15 and a Generalized Anxiety Disorder-7 score ≥15, AND long-term use of hypnotic or psychotropic medications. 3. Pregnant or lactating women. 4. Comorbid severe primary diseases of the cardiovascular, cerebrovascular, pulmonary, hepatic, renal, or hematopoietic systems. 5. Language barriers that would prevent completion of assessments or therapy. 6. Comorbid autoimmune diseases, congenital or acquired immunodeficiency diseases, hematological diseases, or long-term use of corticosteroids or immunosuppressants. 7. Active hepatitis B, active tuberculosis, or other severe or uncontrolled infectious diseases. 8. History of chronic alcohol dependence. 9. Concurrent other primary malignant tumors (except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, etc.). 10. Participation in any other clinical trial within 3 months prior to enrollment. 11. Legally incompetent, or any medical or ethical reason that may hinder the continuation of the study.